NeuroSense Therapeutics Ltd. (NRSN:NASDAQ) closed at $2.46 on October 23, 2026, up 0.82% on the day. The stock trades 90.3% below its 52-week high of $25.40 and 14.4% above its 52-week low of $2.15. NeuroSense Therapeutics Ltd. is part of the Health Care sector.
In 251 trading sessions since October 23, 2025, NRSN closed higher on 102 days (41%). Its best day was September 4, 2026 (+27.11%) and its worst was September 28, 2026 (-26.62%). The stock moved 10% or more in a single session 20 times. It opened at least 5% above the previous day's high 1 time.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Find more stocks like NRSN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.